Oragenics, Inc. (OGEN)
NYSEAMERICAN: OGEN · Real-Time Price · USD
0.612
-0.018 (-2.90%)
At close: Apr 28, 2026, 4:00 PM EDT
0.612
0.00 (0.00%)
After-hours: Apr 28, 2026, 8:00 PM EDT
Oragenics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
3
Market Cap
2.65M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionOGEN News
- 15 days ago - Oragenics Doses First Patient in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain Injury - GlobeNewsWire
- 4 weeks ago - Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation - GlobeNewsWire
- 6 weeks ago - ORAGENICS INITIATES PHASE IIA CLINICAL TRIAL SITE ACTIVATION - GlobeNewsWire
- 6 weeks ago - ORAGENICS EXPLORES EXPANSION OF CNS PLATFORM PURSUING ACQUISTION OF ASSETS IN BRAIN HEALTH, RECOVERY, AND NEUROPROTECTION - GlobeNewsWire
- 7 weeks ago - Oragenics Receives HREC Approval for Phase IIa Clinical Trial of ONP-002 as a Treatment for Concussion and Mild Traumatic Brain Injury in Australia - GlobeNewsWire
- 2 months ago - Oragenics Targets Projected $9 Billion Market by Advancing First and Only Clinical-Stage Concussion and Mild Traumatic Brain Injury Therapy - GlobeNewsWire
- 3 months ago - Oragenics Partners with DUCK FLATS Pharma to Support FDA IND Readiness and Clinical Trial Design for Concussion Program - GlobeNewsWire
- 5 months ago - Oragenics Q3 2025 Shareholder Update - Business Wire